Journal article

Androgen signaling negatively controls group 2 innate lymphoid cells

Sophie Laffont, Eve Blanquart, Magali Savignac, Claire Cenac, Gilles Laverny, Daniel Metzger, Jean-Philippe Girard, Gabrielle T Belz, Lucette Pelletier, Cyril Seillet, Jean-Charles Guery



Prevalence of asthma is higher in women than in men, but the mechanisms underlying this sex bias are unknown. Group 2 innate lymphoid cells (ILC2s) are key regulators of type 2 inflammatory responses. Here, we show that ILC2 development is greatly influenced by male sex hormones. Male mice have reduced numbers of ILC2 progenitors (ILC2Ps) and mature ILC2s in peripheral tissues compared with females. In consequence, males exhibit reduced susceptibility to allergic airway inflammation in response to environmental allergens and less severe IL-33-driven lung inflammation, correlating with an impaired expansion of lung ILC2s. Importantly, orchiectomy, but not ovariectomy, abolishes the sex differ..

View full abstract


Awarded by Fondation pour la Recherche Medicale

Awarded by Agence Nationale de la Recherche

Funding Acknowledgements

Work at CPTP was supported by grants from Conseil Regional Midi-Pyrenees and Fondation pour la Recherche Medicale (Equipe labelisee DEQ2000329169). Work at the Walter and Elisa Hall Institute of Medical Research was supported by a project and program grants of the National Health and Medical Research Council (NHMRC) of Australia, Victorian State Government Operational Infrastructure Support, and Australian Government NHMRC Independent Medical Research Institutes Infrastructure Support Scheme. Work at Institut de Genetique et de Biologie Moleculaire et Cellulaire was supported by funds from the Centre National de la Recherche Scientifique, the Institut National de la Sante et de la Recherche Medicale, the Universite de Strasbourg, the Agence Nationale de la Recherche (ANR-10-1108-01 Androgluco), and by French state funds through the Agence Nationale de la Recherche (ANR-10-LABX-0030-INRT) under the frame program Investissements d'Avenir labeled ANR-10-IDEX-0002-02.